Anziam Bio
Indian medtech company focused on development and manufacture of wound-care consumables and haemostatic dressings. Operates an in‑house R&D facility (incubated at a bio‑incubator), a manufacturing site in Bhiwadi, and offers product documentation and clinical support for wound treatment.
Industries
Nr. of Employees
small (1-50)
Anziam Bio
Manufacturing: E-127 (B), Bhiwadi Industrial Area, Near RIICO Chowk, Bhiwadi-301019, Rajasthan, India
Products
Calcium alginate wound dressings (reinforced; CA, CA+, CA+extra)
Alginate fiber dressings designed to absorb wound exudate and form a gel via ion exchange; available in variants for mild to high exudate and reinforced formats for intact removal.
Silver‑containing antimicrobial alginate dressings
Calcium alginate dressings integrated with soluble silver ions to provide sustained antimicrobial activity while maintaining high absorbency and wet tensile strength.
Carboxymethyl cellulose (CMC) wound dressings
Nonwoven blend of carboxymethyl cellulose and cellulose fibers engineered for fluid lock‑in, high vertical absorption, lateral wicking control and high wet tensile strength for trauma‑free removal.
Chitosan‑alginate haemostatic sponge
Biopolymer sponge composed primarily of chitosan and alginate, designed to be bioadhesive, highly porous for rapid absorption, and to accelerate clot formation through charge‑based platelet aggregation.
Calcium alginate wound dressings (reinforced; CA, CA+, CA+extra)
Alginate fiber dressings designed to absorb wound exudate and form a gel via ion exchange; available in variants for mild to high exudate and reinforced formats for intact removal.
Silver‑containing antimicrobial alginate dressings
Calcium alginate dressings integrated with soluble silver ions to provide sustained antimicrobial activity while maintaining high absorbency and wet tensile strength.
Carboxymethyl cellulose (CMC) wound dressings
Nonwoven blend of carboxymethyl cellulose and cellulose fibers engineered for fluid lock‑in, high vertical absorption, lateral wicking control and high wet tensile strength for trauma‑free removal.
Chitosan‑alginate haemostatic sponge
Biopolymer sponge composed primarily of chitosan and alginate, designed to be bioadhesive, highly porous for rapid absorption, and to accelerate clot formation through charge‑based platelet aggregation.
Services
Collaborative research and development support for wound‑care consumables and haemostatic materials through an in‑house research facility and incubator partnerships.
Collaborative research and development support for wound‑care consumables and haemostatic materials through an in‑house research facility and incubator partnerships.
Expertise Areas
- Wound care product development
- Biomaterials for wound healing
- Haemostatic device development
- In‑vitro analytical characterization
Key Technologies
- Calcium alginate dressings
- Silver‑containing antimicrobial alginate dressings
- Carboxymethyl cellulose (CMC) dressings
- Chitosan‑based haemostatic sponges
News & Updates
Participation and exhibition images from an industrial fair in 2025.
Clinical guidance on factors affecting diabetic wound healing and recommendations for dressing selection, blood sugar control, circulation improvement and advanced therapies.
Overview of haemostatic sponge mechanisms, applications in surgery and trauma, and guidance on application and removal.
Article discussing early detection and wound care strategies to reduce the risk of limb amputation in diabetic patients.
Published case studies reporting sequential dressing regimens and observed wound improvement (e.g., infected gangrene & diabetic foot ulcer: 15 days; arterial ulcer: 12 days; venous leg ulcer: 20 days).
Participation and exhibition images from an industrial fair in 2025.
Clinical guidance on factors affecting diabetic wound healing and recommendations for dressing selection, blood sugar control, circulation improvement and advanced therapies.
Overview of haemostatic sponge mechanisms, applications in surgery and trauma, and guidance on application and removal.
Article discussing early detection and wound care strategies to reduce the risk of limb amputation in diabetic patients.
Published case studies reporting sequential dressing regimens and observed wound improvement (e.g., infected gangrene & diabetic foot ulcer: 15 days; arterial ulcer: 12 days; venous leg ulcer: 20 days).